Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...
Credit: Merck. Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands. The Food and Drug Administration ...
WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone “Pulmonary arterial hypertension ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in combination with other pulmonary ...
The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results